A company currently on my radar is Viking Therapeutics. The company specializes in research and development of biopharmaceutical drugs for metabolic and endocrine disorders. A field in which the company can have prominent success with each pharmaceutical patent.
This is a list of their current research:
- VK2809:
- A Selective Thyroid Receptor-Beta Antagonist that's target is to assist in treating Non-Alchoholic Fatty Liver Disease, and Hypercholesterolemia (high cholesterol).
- VK5211:
- A Non-Steroidal Selective Androgen Receptor Modulator that is in Phase 2 of development. The goal of this drug is to assist in post-operative care of those individuals whom underwent non-elective surgery for hip fractures.
- VK0214:
- This drug is currently planned for a dive into research following Q4 of this year. The goal of the drug is to assist in the treatment of X-Linked Adrenoleukodystrophy (ALD). A neurological disease that is genetically inherited and characterized by the chronic breakdown of the protective tissue of the brain and nerve cells. To better assist in explaining the disorder, I have attached a video for your convenience.
In the world of stocks, where does this come into play?
Well, from an investment standpoint. VKTX has a lot of potential for consistent growth, as their primary goal is not pinnacled on the success of one pharmaceutical patent, but on multiple patents. Ergo, they have in a sense "broadened their portfolio" of business. I find this to be good elements when looking at a company for investment.
When looking at the company from an investment perspective, these are the figures that every investor likes to know:
- Founded in 2012
- Market Cap of 713.28M
- 52 Week Low of $1.12
- 52 Week High of $13.43
- Current Stock Price is $11.34
The company shares are currently in a great position for buying, as the shares are not peaked and are on a good downslope before another "expected" upward movement. The company carries a health growth pattern, and sheds optimism despite their drop in share price this week.
I think these shares are prime for the taking given the current stock price, their share growth, and the company's potential of growing their capital through their various R&D projects.
Submitted September 07, 2018 at 07:43PM by LetsTalkStock https://ift.tt/2N03OTe
No comments:
Post a Comment